Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The 28th Congress of the European Hematology Association (EHA) 2023 was held in Frankfurt, Germany, from June 8-11, 2023, and continued virtually on June 14-15, 2023. This meeting was an opportunity for world-leading experts to come together to share cutting-edge updates in the diagnosis and treatment of hematological malignancies.
View all videos

EHA 2023

The 28th Congress of the European Hematology Association
08–11 June 2023 | Frankfurt, Germany / Online

EHA 2023

The 28th Congress of the European Hematology Association
08–11 June 2023 | Frankfurt, Germany / Online
The 28th Congress of the European Hematology Association (EHA) 2023 was held in Frankfurt, Germany, from June 8-11, 2023, and continued virtually on June 14-15, 2023. This meeting was an opportunity for world-leading experts to come together to share cutting-edge updates in the diagnosis and treatment of hematological malignancies.
View all videos

Latest videos

View all videos
8:11
The José Carreras award and a history of immunotherapy in Ph+ ALL
Robin Foà • 11 Jun 2023
2:14
Top highlights from ASCO & EHA 2023
Mohamad Mohty • 10 Jun 2023
2:25
MASTER final analysis: quadruplet induction therapy, ASCT & MRD-adapted treatment cessation in NDMM
Luciano Costa • 10 Jun 2023
1:56
Identifying and managing patients at high risk of developing toxicities following CAR-T therapy
Kai Rejeski • 10 Jun 2023

Press Briefings

View all
5:09
MORPHO: gilteritinib as post-transplant maintenance therapy in patients with FLT3-ITD AML
Mark Levis • 9 Jun 2023
9:07
REVIVE: targeted therapy for uncontrolled erythrocytosis in PV with rusfertide
Ronald Hoffman • 9 Jun 2023
6:59
ADCLEC.syn1 CAR: ADGRE2-targeting 28z1XX-CAR and a CLEC12A-targeting CCR in humanized AML models
Sascha Haubner • 9 Jun 2023
5:59
6-year results of CLL14: venetoclax-obinutuzumab for previously untreated CLL
Othman Al-Sawaf • 9 Jun 2023

Multiple myeloma

View all
3:24
Multimodal prediction of survival in myeloma: combining MRD testing with MALDI-TOF MS & imaging
Rakesh Popat • 11 Jun 2023
5:49
MagnetisMM-3 extended follow up results: elranatamab monotherapy in R/R multiple myeloma
Mohamad Mohty • 10 Jun 2023

Myeloproliferative Neoplasms

View all
5:40
LBA: results of REVIVE – rusfertide in patients with polycythemia vera
Marina Kremyanskaya • 10 Jun 2023
4:35
The role of JAK2 VAF testing in risk assessment and disease monitoring in MPNs
Jean-Jacques Kiladjian • 13 Jun 2023

Acute Myeloid Leukemia

View all
1:43
LBA: gilteritinib as post-transplant maintenance therapy in FLT3-ITD AML
Mark Levis • 9 Jun 2023
1:38
LBA: KOMET-001 – ziftomenib monotherapy in R/R NPM1-mutated AML
Eunice Wang • 9 Jun 2023

Myelodysplastic Syndromes

View all
1:44
IMerge update: continuous transfusion independence & disease modification with imetelstat in LR-MDS
Amer Zeidan • 10 Jun 2023
4:19
COMMANDS study: efficacy & safety results and biomarker analysis
Uwe Platzbecker • 14 Jun 2023

Chronic Lymphocytic Leukemia

View all
2:34
BRUIN study update: analysis of the mechanisms of resistance to pirtobrutinib in CLL
Jennifer Brown • 9 Jun 2023
Latest advances in BTK inhibitors from EHA 2023
Lydia Scarfò et al. • 24 Jun 2023

Lymphoma

View all
Updates in CAR-T and bispecific antibodies for LBCL from EHA 2023
Gloria Iacoboni et al. • 24 Jun 2023
3:48
Phase II study of brentuximab vedotin + CHP in patients with PTCL with less than 10% CD30 expression
Swaminathan Iyer • 10 Jun 2023

Immuno-Oncology

View all
1:54
Ongoing CAR-T trials in earlier lines of therapy in myeloma & strategies to improve efficacy
Salomon Manier • 9 Jun 2023
1:32
Issues in CAR-T slot allocation in lymphoma and multiple myeloma
Nico Gagelmann • 11 Jun 2023

Trial Updates

View all
2:32
Final results of CARTITUDE-1: cilta-cel in heavily pretreated patients with R/R multiple myeloma
Nikhil Munshi • 9 Jun 2023
1:49
Follow-up results of EPCORE NHL-1: subcutaneous epcoritamab in R/R LBCL
Wojciech Jurczak • 10 Jun 2023
The content of VJHemOnc is intended for healthcare professionals